Cyfuse Biomedical K.K.
TTSE:4892581.00
JPY
-14.00
(-2.35%)
ISIN
JP3311800001
Return %
Stock
S&P 500
1Y
-7.19
14.20
3Y
-19.53
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Shizuka Akieda
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- South Tower, Sumitomo Fudosan Tokyo Mita Minato-Ku Japan 108-6301
- IPO Date
- Dec 1, 2022
- Website
- en.cyfusebio.com
- Similar Companies
- Business
- Cyfuse Biomedical K.K. (4892.T) develops, manufactures and sells regenerative medicine products and 3D bioprinting systems in Japan. The company offers Bio 3D Printers including regenova, a robotic system for fabricating 3D cellular structures from cell spheroids arranged in needle arrays; and S-PIKE, a next-generation printer for scaffold-free tissue engineering applicable to cartilage, bone, blood vessels, nerves and drug discovery models; alongside functional cellular devices as tools for pharmaceutical research and contract development of cell products. Founded in 2010 and headquartered in Minato-ku, Tokyo, with an additional office in Fukuoka, the firm targets healthcare providers, pharmaceutical companies and research institutions through its proprietary scaffold-free 3D printing platform. Recent developments include a 2025 joint announcement with PHC Corporation on innovative 3D cell product production technology for commercialization; business partnership with Marubeni Corporation for global expansion of S-PIKE; and sales alliance with Sysmex Corporation to market the printer; building on the 2023 strategic alliance with PHC to accelerate regenerative medicine pipelines.